trending Market Intelligence /marketintelligence/en/news-insights/trending/PaEOZxk1MBtrDQ8_LSPlyw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA accepts Immunomedics' application for breast cancer drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US FDA accepts Immunomedics' application for breast cancer drug

The U.S. Food and Drug Administration accepted Immunomedics Inc.'s application seeking approval of its medicine sacituzumab govitecan to treat certain patients with breast cancer.

The Morris Plains, N.J.-based company had refiled the biologics license application for accelerated approval of the drug in December after an initial rejection in January. Immunomedics had said the FDA's complete response letter only focused on chemistry, manufacturing and control, and no new clinical or preclinical data was requested.

The company is seeking approval of the medicine to treat patients with triple-negative breast cancer whose disease has spread to other parts of the body and who did not get better after receiving two previous treatments.

Immunomedics said in a Dec. 26 news release that the FDA is expected to make a decision on the application around June 2, 2020.

Sacituzumab govitecan already has the FDA's fast track and breakthrough therapy designations.